Graft-versus-host disease (GVHD) represents a serious complication of allogeneic BMT and remains one of the most difficult challenges for clinicians. ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker. Enbrel has had some effects in case reports but there has not been a prospective study. Enbrel is now in a clinical study: The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease, NCT00141713. In this study, Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to see if the effectiveness of standard therapy can be improved.
Bolanos-Meade J. Update on the management of acute graft-versus-host disease. Curr Opin Oncol. 2006;18(2):120-125.
Kennedy GA, Butler J, Western R, et al. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant. 2006;37(12):1143-1147. 54.
Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, et al. Chronic graft-versus-host disease: Pathogenesis and clinical management. Drugs. 2006;66(8):1041-1057.
A. Gulbis, Y. Hsu, J. Neumann, S. Hymes, M. de Lima, C. Hosing, I. Khouri, M. Qazilbash, P. Kebriaei, B. Andersson: Etanercept as salvage therapy for chronic graft-versus-host disease Biology of Blood and Marrow Transplantation, Volume 13, Issue 2, Pages 107-108, 2007